UCB Acquiring Celltech; Phase III TNF Inhibitor At Center Of $2.7 Bil. Deal
UCB is paying $2.7 bil. to lock up rights to Celltech's TNF inhibitor CDP-870
You may also be interested in...
Pfizer is returning to acquisition mode, but with an eye on building its biotechnology presence rather than another major pharmaceutical merger
Pharmacia R&D President Goran Ando, MD, will move to the other side of a partnership between Pharmacia and Celltech for the Phase III rheumatoid arthritis agent CDP-870 as Celltech CEO
Abbott will highlight Humira dosing convenience, efficacy and price to encourage switching of rheumatoid arthritis patients from Amgen/Wyeth's Enbrel or Johnson & Johnson's Remicade